Dimensional Fund Advisors LP Sells 18,602 Shares of AxoGen, Inc. $AXGN

Dimensional Fund Advisors LP reduced its position in AxoGen, Inc. (NASDAQ:AXGN) by 3.1% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 583,190 shares of the medical equipment provider’s stock after selling 18,602 shares during the quarter. Dimensional Fund Advisors LP’s holdings in AxoGen were worth $19,317,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in AXGN. MCF Advisors LLC acquired a new stake in shares of AxoGen in the 4th quarter valued at $30,000. Aquatic Capital Management LLC raised its holdings in shares of AxoGen by 287.8% during the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 1,269 shares in the last quarter. Arax Advisory Partners lifted its position in shares of AxoGen by 362.4% during the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 819 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of AxoGen during the 4th quarter worth $36,000. Finally, Kestra Advisory Services LLC acquired a new stake in AxoGen in the fourth quarter valued at about $39,000. 80.29% of the stock is currently owned by institutional investors and hedge funds.

AxoGen Stock Performance

NASDAQ:AXGN opened at $46.43 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.04 and a current ratio of 6.60. AxoGen, Inc. has a fifty-two week low of $13.64 and a fifty-two week high of $46.95. The company has a 50 day simple moving average of $42.64 and a two-hundred day simple moving average of $37.87. The company has a market capitalization of $2.50 billion, a PE ratio of -68.28 and a beta of 1.11.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.12. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. The firm had revenue of $69.73 million for the quarter, compared to the consensus estimate of $67.10 million. Research analysts anticipate that AxoGen, Inc. will post -0.45 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on AXGN. Wells Fargo & Company increased their price target on AxoGen from $40.00 to $48.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Lake Street Capital upped their target price on AxoGen from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd. Canaccord Genuity Group increased their target price on AxoGen from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Jefferies Financial Group reissued a “buy” rating and set a $55.00 price target on shares of AxoGen in a research note on Wednesday, July 29th. Finally, Zacks Research upgraded AxoGen from a “strong sell” rating to a “hold” rating in a report on Friday, May 29th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.

AxoGen Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.